EVII is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements

Genes Chromosomes and Cancer

Volumn 45, Issue 4, 2006, Pages 349-356

  Poppa, Bruce ^a   Dastugue, Nicole ^b   Vandesompele, Jo ^a   Cauwelier, Barbara ^a   De Smet, Betty ^a   Yigit, Nurten ^a   De Paepe, Anne ^a   Cervera, Jose ^c   Recher, Christian ^b   De Mas, Véronique ^b   Hagemeijer, Anne ^d   Speleman, Frank ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b CHU PURPAN   (France)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CONTIG; DNA BINDING PROTEIN; EVI1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL NUCLEUS; CHROMOSOME 3Q; CHROMOSOME BREAKAGE; CHROMOSOME MAP; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION 3; CLINICAL ARTICLE; EVII GENE; FEASIBILITY STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION; GENE LOCUS; GENE REARRANGEMENT; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN TISSUE; INTERPHASE; MALE; MDSI GENE; METAPHASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; BLOOD DISEASE; CHROMOSOME 3; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; COMPARATIVE STUDY; GENE EXPRESSION PROFILING; GENE TRANSLOCATION; GENETICS; MIDDLE AGED; PRESCHOOL CHILD; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 3; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; HEMATOLOGIC NEOPLASMS; HUMANS; INVERSION, CHROMOSOME; MALE; MIDDLE AGED; PHYSICAL CHROMOSOME MAPPING; PROTO-ONCOGENES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 33644760289     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20295     Document Type: Article

References (32)

1. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R, Slater R, Smit EM, Beverloo HB, Verhoef GVerdonck LF, Ossenkoppele GJ, Sonneveld P, de Greef GE, Lowenberg B, Delwel R. 2003. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 101:837-845.
2. Charrin C, Belhabri A, Treille-Ritouet D, Theuil G, Magaud JP, Fiere D, Thomas X. 2002. Structural rearrangements of chromosome 3 in 57 patients with acute myeloid leukemia: clinical, hematological and cytogenetic features. Hematol J 3:21-31.
3. Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD, Nucifora G. 1996. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci USA 93:1642-1647.
4. Fichelson S, Dreyfus F, Berger R, Melle J, Bastard C, Miclea JM, Gisselbrecht S. 1992. Evi-1 expression in leukemic patients with rearrangements of the 3q25-q28 chromosomal region. Leukemia 6:93-99.
5. Fleischman EW, Volkova MA, Frenkel MA, Konstantinova LN, Kulagina OE, Baranov AE, Gordeeva AA. 1996. Translocation (2;3)(p13;q26) in two cases of myeloid malignancies. Acute myeloblastic leukemia (M2) and blastic phase of chronic myeloid leukemia. Cancer Genet Cytogenet 87:182-184.
6. Herens C, Hermanne JP, Tassin F, Fassotte MF, Thiry A, Jamar M, Schaaf-Lafontaine N, Fillet G, Koulischer L. 1999. Translocation (2;3)(p21;q26) as the sole anomaly in a case of primary myelofibrosis. Cancer Genet Cytogenet 110:62-64.
7. Kwong YL, Chan LC, Lie KW. 1992. t(2;3)(p13;q26) in a case of chronic myeloid leukemia. Importance of the involvement of 3q26. Cancer Genet Cytogenet 59:95-96.
8. Lahortiga I, Vazquez I, Agirre X, Larrayoz MJ, Vizmanos JL, Gozzetti A, Calasanz MJ, Odero MD. 2004. Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements. Genes Chromosomes Cancer 40:179-189.
9. Levaltier X, Penther D, Bastard C, Troussard X. 1996. t(2;3)(p23:q26) in a patient with AML M2. Br J Haematol 92:1027.
10. Matsugi T, Morishita K, Ihle JN. 1990. Identification, nuclear localization, and DNA-binding activity of the zinc finger protein encoded by the Evi-1 myeloid transforming gene. Mol Cell Biol 10:1259-1264.
11. Mecucci C, Michaux JL, Broeckaert-Van Orshoven A, Symann M, Boogaerts M, Kulling G, Van den Berghe H. 1984. Translocation t(3;17)(q26;q22): a marker of acute disease in myeloproliferative disorders? Cancer Genet Cytogenet 12:111-119.
12. Mitani K, Ogawa S, Tanaka T, Miyoshi H, Kurokawa M, Mano H, Yazaki Y, Ohki M, Hirai H. 1994/Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. Embo J 13:504-510.
13. Mitelman F, editor. 1995.ISCN. 1995. An international system for human cytogenetic nomenclature. Basel, Switzerland: S. Karger.
14. Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG, Ihle JN. 1988. Retroviral activation of a novel gene encoding a zinc finget ptotein in IL-3-dependent myeloid leukemia cell lines. Cell 54:831-840.
15. Mucenski ML, Taylor BA, Ihle JN, Hartley JW, Morse HC, 3rd, Jenkins NA, Copeland NG. 1988. Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors. Mol Cell Biol 8:301-308.
16. Mugneret F, Solary E, Favre B, Caillot D, Sidaner I, Guy H. 1992. New case of t(3;17)(q26;q22) as an additional change in a Philadelphia-positive chronic myelogenous leukemia in acceleration. Cancer Genet Cytogenet 60:90-92.
17. Nucifora G. 1997. The EVI1 gene in myeloid leukemia. Leukemia 11:2022-31.
18. Pattyn F, Speleman F, De Paepe A, Vandesompele J. 2003. RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids Res 31:122-123.
19. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. 1995. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 86:3542-3552.
20. Peeters P, Wlodarska I, Baens M, Criel A, Selleslag D, Hagemeijer A, Van den Berghe H, Marynen P. 1997. Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders. Cancer Res 57:564-569.
21. Pekarsky Y, Rynditch A, Wieser R, Fonatsch C, Gardiner K. 1997. Activation of a novel gene in 3q21 and identification of intergenic fusion transcripts with ecotropic vital insertion site I in leukemia. Cancer Res 57:3914-3919.
22. Russell M, List A, Greenberg P, Woodward S, Glinsmann B, Parganas E, Ihle J, Taetle R. 1994. Expression of EVI1 in myelodysplastic syndromes and othet hematologic malignancies without 3q26 translocations. Blood 84:1243-1248.
23. Soderholm J, Kobayashi H, Mathieu C, Rowley JD, Nucifora G. 1997. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator. Leukemia 11:352-358.
24. Sood R, Talwar-Trikha A, Chakrabarti SR, Nucifota G. 1999. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1. Leukemia 13:348-357.
25. Stevens-Kroef M, Poppe B, Van Zelderen-Bhola S, Van Den Berg E, Van Der Blij-Philipsen M, Geurts Van Kessel A, Slater R, Hamers G, Michaux L, Speleman F, Hagemeijer A. 2004. Translocation t(2;3)(p15-23;q26-27) in myeloid malignancies: report of 21 new cases, clinical, cytogenetic and molecular genetic features. Leukemia 2004 18:1108-1114.
26. Suzukawa K, Parganas E, Gajjar A, Abe T, Takahashi S, Tani K, Asano S, Asou H, Kamada N, Yokota J and others. 1994. Identification of a breakpoint cluster region 3′ of the ribophorin 1 gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26). Blood 84:2681-2688.
27. Suzukawa K, Taki T, Abe T, Asoh H, Kamada N, Yokota J, Morishita K. 1997. Identification of translocational breakpoints within the intron region before the last coding exon (exon 12) of the EVI1 gene in two cases of CML-BC with inv(3)(q21q26). Genomics 42:356-360.
28. Van Limbergen H, Poppe B, Michaux L, Herens C, Brown J, Noens L, Berneman Z, De Bock R, De Paepe A, Speleman F. 2002. Identification of cytogenetic subclasses and recurring chromosomal aberrations in AML and MDS with complex karyotypes using M-FISH. Genes Chromosomes Cancer 33:60-72.
29. Van Roy N, Vandesompele J, Berx G, Staes K, Van Gele M, De Smet E, De Paepe A, Laureys G, van der Drift P, Versteeg R and others. 2002. Localization of the 17q breakpoint of a constitutional 1;17 translocation in a patient with neuroblastoma within a 25-kb segment located between the ACCN1 and TLK2 genes and near the distal breakpoints of two microdeletions in neurofibromatosis type 1 patients. Genes Chromosomes Cancer 35:113-120.
30. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034.
31. Vinatzer U, Mannhalter C, Mitterbauer M, Gruener H, Greinix H, Schmidt HH, Fonatsch C, Wieser R. 2003. Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia. Genes Chromosomes Cancer 36:8089.
32. Wieset R, Schreiner U, Pitc-Danoewinata H, Aytekin M, Schmidt HH, Rieder H, Fonatsch C. 2001. Interphase fluorescence in situ hybridization assay for the detection of 3q21 rearrangements in myeloid malignancies. Genes Chromosomes Cancer 32:373-830.